FDA Rejects Ivonescimab Lung Cancer Drug from Summit Therapeutics

The United States Food and Drug Administration (FDA) rejected the application for ivonescimab, a lung cancer treatment developed by Summit Therapeutics, on Sunday. This decision marks a setback for efforts to expand therapeutic options for patients whose conditions have progressed following other medication regimens.

Clinical Trial Results Analysis

In a letter detailing the reasons for the denial, the FDA stated that an advanced-stage clinical trial demonstrated that ivonescimab significantly delayed disease progression. However, the agency noted that the drug did not produce a statistically significant improvement in overall survival rates.

The rejection followed the drug's failure to achieve statistically significant results regarding overall survival, which serves as a primary metric for long-term treatment benefit. This outcome was central to the marketing application submitted by the company based on the pivotal study.

Survival Data Discrepancies

A separate Chinese study indicated that ivonescimab extended median survival by 15 percent and reduced the risk of death by more than one-third compared to immunotherapy treatments for advanced lung cancer.

Despite these findings, the FDA concluded that the benefit of progression-free survival alone was insufficient to tip the balance of benefits against risks in favor of approval.

Company Response and Updated Data

Summit Therapeutics subsequently provided updated survival rate data to the regulatory body. The company reported that this new information showed consistent improvement among both Asian and Western patient populations.

Summit Therapeutics asserted that longer follow-up periods support the drug's efficacy. The firm highlighted that updated analyses revealed a reduction in mortality risk across all subgroups of Western and Asian patients.